PO.BCS01.07 · 生物信息与计算
来自3D全息断层成像的无标记虚拟HE可在厚层癌组织中实现可靠的细胞核和显微解剖学读出
Label free virtual HE from 3D holotomography enables reliable nuclear and microanatomical readouts in thick cancer tissues
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
传统H&E染色具有破坏性、受限于2D,且不兼容纵向或稀缺样本研究。全息断层成像(HT)能够对厚层组织进行无标记的3D折射率(RI)成像,但由于切片引起的形变,无法实现虚拟染色的像素级精确监督。基于我们近期对厚度达50 μm的结肠癌和胃癌组织进行3D虚拟H&E的演示,我们开发了一个框架,利用弱对齐的化学H&E监督直接从HT体积中学习类苏木精和类伊红对比。该方法产生稳定、可解释的细胞核和间质特征,在完全无标记的工作流中实现以细胞核为中心的定量读出。用3D HT对FFPE乳腺癌组织进行成像,以在亚细胞分辨率下获得定量RI体积。训练了一个基于扩散的图像到图像模型,采用弱HT-H&E对齐和仅在训练期间应用的核感知辅助损失。推理仅需HT,保持无耗材、非破坏性的流程。保真度通过以下方面评估:(i)细胞核形态一致性,(ii)瓦片级和视野级真实感,(iii)平滑的z切片一致性,以及(iv)标准化的细胞核定量。使用先前验证过的、厚度跨越10-50 μm的结肠和胃数据集评估了跨组织的泛化能力。虚拟H&E保留了嗜碱性细胞核对比和嗜酸性间质特征,即使在厚切片中也能准确重建腺体、间质和肌肉边界。细胞核轮廓在各轴向平面上保持连续,无闪烁伪影。全视野细胞核计数与化学H&E显示97.8%的一致性,细胞核面积/形状指标无显著偏差。外观误差明显低于先前的虚拟染色方法,专家评审确认忠实再现了染色质纹理、核仁可见性以及对癌症分级至关重要的细胞核拥挤模式。该方法在各种组织厚度(4-50 μm)、器官类型和机构来源中均保持稳健。直接从无标记HT生成的虚拟H&E能够在不染色、无切片伪影或组织损失的情况下实现高保真、以细胞核为驱动的读出。这支持了快速、无耗材的组织评估以及以细胞核为中心的生物标志物的可重现定量。其与厚层组织体积的兼容性使该技术适用于药物反应分析、作用机制研究、肿瘤微环境分析和高内涵表型筛选。正在进行的多中心验证和用于全切片推理的3D扩散模型开发,旨在确立无标记3D虚拟组织病理学作为传统H&E在研究和转化肿瘤学中的可扩展替代方案。
查看英文原文 English abstract
Conventional H&E staining is destructive, 2D-limited, and incompatible with longitudinal or scarce-sample studies. Holotomography (HT) enables label-free 3D refractive index (RI) imaging of thick tissue, but pixel-accurate supervision for virtual staining is unattainable due to sectioning-induced deformation. Building on our recent demonstration of 3D virtual H&E for colon and gastric cancer tissues up to 50 µm thick, we developed a framework that learns hematoxylin- and eosin-like contrast directly from HT volumes using weakly aligned chemical H&E supervision. The method produces stable, interpretable nuclear and stromal features, enabling nuclei-centric quantitative readouts in a fully label-free workflow.FFPE breast cancer tissues were imaged with 3D HT to obtain quantitative RI volumes at subcellular resolution. A diffusion-based image-to-image model was trained with weak HT-H&E alignment and a nucleus-aware auxiliary loss applied only during training. Inference requires HT alone, maintaining a consumable-free, non-destructive pipeline. Fidelity was evaluated by (i) nuclear morphology agreement, (ii) patch- and field-level realism, (iii) smooth z-slice consistency, and (iv) standardized nuclei quantification. Cross-tissue generalizability was assessed using previously validated colon and gastric datasets spanning 10-50 µm thickness.The virtual H&E preserved basophilic nuclear contrast and eosinophilic stromal features, accurately reconstructing glandular, stromal, and muscular boundaries even in thick sections. Nuclear contours remained continuous across axial planes without flicker artifacts. Whole-field nuclear counts showed 97.8% concordance with chemical H&E, and nuclear area/shape metrics showed no significant deviation. Appearance error was notably lower than prior virtual-staining approaches, and expert reviewers confirmed faithful chromatin texture, nucleoli visibility, and nuclear crowding patterns essential for cancer grading. The method remained robust across tissue thicknesses (4-50 µm), organ types, and institutional sources.Virtual H&E generated directly from label-free HT enables high-fidelity, nuclei-driven readouts without staining, sectioning artifacts, or tissue loss. This supports rapid, consumable-free tissue assessment and reproducible quantification of nuclei-centric biomarkers. Its compatibility with thick tissue volumes positions the technology for drug-response profiling, mechanism-of-action studies, tumor microenvironment analysis, and high-content phenotypic screening. Ongoing multi-site validation and development of 3D diffusion models for whole-slide inference aim to establish label-free 3D virtual histopathology as a scalable alternative to conventional H&E for research and
translational oncology.
利益披露 Disclosure
J. Park, None..
G. Kim, None..
D. Kim, None..
H. Cho, None..
D. Ahn, None..
J. Clemenceau, None..
D. Ryu, None..
I. Barnfather, None..
M. Kim, None..
I. Jang, None..
J. Sung, None..
J. Park, None..
Y. Park, None.